BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30828436)

  • 1. The effects of testosterone replacement therapy on the prostate: a clinical perspective.
    Miah S; Tharakan T; Gallagher KA; Shah TT; Winkler M; Jayasena CN; Ahmed HU; Minhas S
    F1000Res; 2019; 8():. PubMed ID: 30828436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
    Heaton JP
    Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
    Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
    J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
    Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
    J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
    Landau D; Tsakok T; Aylwin S; Hughes S
    Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the basis of sexual dysfunction during late-onset hypogonadism.
    Tharakan T; Miah S; Jayasena C; Minhas S
    F1000Res; 2019; 8():. PubMed ID: 30984376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould DC; Kirby RS
    Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone Therapy Among Prostate Cancer Survivors.
    Nguyen TM; Pastuszak AW
    Sex Med Rev; 2016 Oct; 4(4):376-88. PubMed ID: 27474995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset hypogonadism: Prostate safety.
    Miranda EP; Torres LO
    Andrology; 2020 Nov; 8(6):1606-1613. PubMed ID: 32056383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Testosterone substitution with special regard to prostate cancer].
    Beintker M; Behre H
    Urologe A; 2008 Dec; 47(12):1588-91. PubMed ID: 18931991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
    Kaplan AL; Hu JC
    Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
    Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
    Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
    J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone replacement therapy and the risk of prostate cancer.
    Warburton D; Hobaugh C; Wang G; Lin H; Wang R
    Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostate carcinoma and testosterone: risks and controversies].
    Rhoden EL; Averbeck MA
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):956-62. PubMed ID: 20126847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy.
    Hassan J; Barkin J
    Can J Urol; 2016 Feb; 23(Suppl 1):20-30. PubMed ID: 26924592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of androgen therapy in men with prostate cancer.
    Rajan P; Tharakan T; Chen R
    Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.